Literature DB >> 34327576

MRI of nasopharyngeal carcinoma: parapharyngeal subspace involvement has prognostic value and influences T-staging in the IMRT era.

Wenjie Huang1, Tingting Quan1, Qin Zhao1, Shuqi Li1, Yi Cai2, Jian Zhou1, Chao Luo1, Guangying Ruan1, Chunyan Cui1, Shaobo Liang3, Haojiang Li4, Lizhi Liu5.   

Abstract

OBJECTIVES: To identify the prognosis of parapharyngeal space involvement (PPSI) based on the number of subspaces involved (pre-styloid space, carotid space (CS), areas outside the CS) and explore its significance for current T-staging in patients with nasopharyngeal carcinoma (NPC).
METHODS: PPSI was retrospectively identified in 1224 patients with non-disseminated NPC at two centers on MRI and separated into four invasion patterns: pattern A (only post-styloid space), pattern B (post-styloid space, CS extension), pattern C (post-styloid space, pre-styloid space extension), and pattern D (all spaces). The Kaplan-Meier analysis and multivariate Cox regression models were used.
RESULTS: PPSI was diagnosed in 63.4% of cases, with patterns A, B, C, and D in 14.3%, 3.8%, 25.3%, and 18.6% of cases, respectively. No prognostic heterogeneity was observed between pattern B and pattern C (p > 0.05). Thus, the degree of PPSI was based on the number of subspaces involved: grade 0 (none), grade 1 (one), grade 2 (two), and grade 3 (three), which could independently predict overall survival (OS) (p < 0.001). T3 patients with grade 0/1 PPSI (slight-T3) had a better prognosis than those with grade 2/3 PPSI (severe-T3) in terms of OS, locoregional-free survival (LRFS), and progression-free survival (PFS) (all p < 0.001), whose hazard ratios were higher and lower than those with T1 and T2, respectively. Combining the T2 and slight-T3 groups as the proposed T2 provided significant differences in OS, LRFS, and PFS between T2 and T3 (all p < 0.05).
CONCLUSIONS: The risk of death increased with the number of parapharyngeal subspaces involved. The degree of PPSI is recommended to optimize T3 heterogeneity. KEY POINTS: • Parapharyngeal space involvement was proposed to differentiate patient risk groups based on the number of involved subspaces: grade 0 (none), grade 1 (one), grade 2 (two), or grade 3 (three). • The degree of parapharyngeal space involvement was an independent negative prognosticator for OS. • The degree of parapharyngeal space involvement may influence T-staging in patients with nasopharyngeal carcinoma.
© 2021. European Society of Radiology.

Entities:  

Keywords:  Nasopharyngeal carcinoma; Neoplasm staging; Parapharyngeal space; Prognosis

Mesh:

Year:  2021        PMID: 34327576     DOI: 10.1007/s00330-021-08113-3

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  3 in total

1.  Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma.

Authors:  Jian-Yong Shao; Yu Zhang; Yu-Hong Li; Hong-Yi Gao; Hui-Xia Feng; Qiu-Liang Wu; Nian-Ji Cui; Gang Cheng; Bin Hu; Li-Fu Hu; Ingemar Ernberg; Yi-Xin Zeng
Journal:  Anticancer Res       Date:  2004 Nov-Dec       Impact factor: 2.480

2.  [Intensity modulated radiotherapy for local-regional advanced nasopharyngeal carcinoma].

Authors:  Chong Zhao; Fei Han; Li-Xia Lu; Shao-Min Huang; Cheng-Guang Lin; Xiao-Wu Deng; Tai-Xiang Lu; Nian-Ji Cui
Journal:  Ai Zheng       Date:  2004-11

3.  Prognostic value of classifying parapharyngeal extension in nasopharyngeal carcinoma based on magnetic resonance imaging.

Authors:  Guo-Yi Zhang; Ying Huang; Xue-Feng Hu; Xiang-Ping Chen; Tao Xu; Li-Zhi Liu; Wei-Hong Wei; Guo-Sen Huang; Miao-Miao Zhou; Ze-Li Huang; Yue-Jian Wang
Journal:  Biomed Res Int       Date:  2015-03-26       Impact factor: 3.411

  3 in total
  1 in total

1.  Pretreatment [18F]FDG PET/CT and MRI in the prognosis of nasopharyngeal carcinoma.

Authors:  Amina Gihbid; Ghofrane Cherkaoui Salhi; Imane El Alami; Hasnaa Belgadir; Nezha Tawfiq; Karima Bendahou; Mohammed El Mzibri; Rachida Cadi; Naima El Benna; Amal Guensi; Meriem Khyatti
Journal:  Ann Nucl Med       Date:  2022-07-14       Impact factor: 2.258

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.